The Journal of the American Medical Association Finally Questions Whether the FDA Should be Approving Useless No-Evidence Cholesterol-Lowering Drugs
chrismasterjohnphd.substack.com
After the Coronary Primary Prevention Trial, fittingly published in 1984, showed that cholestyramine, a drug that lowers cholesterol by causing its conversion to bile acids, could reduce the risk of heart attacks, cholesterol was widely villainized as a killer. From then on, the decades-old campaign of the American Heart Association against eggs and butter was vindicated in the press and the FDA began considering any drug that could effectively reduce cholesterol levels in the blood to be a preventer of heart attacks.
The Journal of the American Medical Association Finally Questions Whether the FDA Should be Approving Useless No-Evidence Cholesterol-Lowering Drugs
The Journal of the American Medical…
The Journal of the American Medical Association Finally Questions Whether the FDA Should be Approving Useless No-Evidence Cholesterol-Lowering Drugs
After the Coronary Primary Prevention Trial, fittingly published in 1984, showed that cholestyramine, a drug that lowers cholesterol by causing its conversion to bile acids, could reduce the risk of heart attacks, cholesterol was widely villainized as a killer. From then on, the decades-old campaign of the American Heart Association against eggs and butter was vindicated in the press and the FDA began considering any drug that could effectively reduce cholesterol levels in the blood to be a preventer of heart attacks.